Vybion
Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a progressively fatal protein aggregating condition leading to loss of neurons. A recent preIND meeting has established IND enabling work to be completed before submitting and IND to start human clinical trials.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Innovation in Vectorized Intrabodies.
Vybion is the leading developer of Intrabodies for neurodegenerative diseases, leveraging the safety and effectiveness of antibody technologies to address unmet medical needs. Vybion Intrabodies are scFv fragments that target and change the fate of intracellular events like the protein aggregation, gene dysregulation and turnover of toxic protein fragments as a disease modifying approach to therapeutics.
Huntington's Disease
The first therapeutic to emerge from PharmCode is INT41, an intrabody currently delivered with AAV for the treatment of Huntington's disease. INT41 is a disease modifying drug that blocks gene dysregulation and the action of toxic Huntingtin mutant protein fragments in the nucleus.